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Background: The presence of metastatic disease in cervical lymph nodes of head and neck squamous cell
carcinoma (HNSCC) patients is a very important determinant in therapy choice and prognosis, with great impact in
overall survival. Frequently, routine lymph node staging cannot detect occult metastases and the post-surgical histologic
evaluation of resected lymph nodes is not sensitive in detecting small metastatic deposits. Molecular markers based on
tissue-specific microRNA expression are alternative accurate diagnostic markers. Herein, we evaluated the feasibility of
using the expression of microRNAs to detect metastatic cells in formalin-fixed paraffin-embedded (FFPE) lymph nodes
and in fine-needle aspiration (FNA) biopsies of HNSCC patients.
Methods: An initial screening compared the expression of 667 microRNAs in a discovery set comprised by metastatic
and non-metastatic lymph nodes from HNSCC patients. The most differentially expressed microRNAs were validated by
qRT-PCR in two independent cohorts: i) 48 FFPE lymph node samples, and ii) 113 FNA lymph node biopsies. The
accuracy of the markers in identifying metastatic samples was assessed through the analysis of sensitivity, specificity,
accuracy, negative predictive value, positive predictive value, and area under the curve values.
Results: Seven microRNAs highly expressed in metastatic lymph nodes from the discovery set were validated in FFPE
lymph node samples. MiR-203 and miR-205 identified all metastatic samples, regardless of the size of the metastatic
deposit. Additionally, these markers also showed high accuracy when FNA samples were examined.
Conclusions: The high accuracy of miR-203 and miR-205 warrant these microRNAs as diagnostic markers of neck
metastases in HNSCC. These can be evaluated in entire lymph nodes and in FNA biopsies collected at different
time-points such as pre-treatment samples, intraoperative sentinel node biopsy, and during patient follow-up.
These markers can be useful in a clinical setting in the management of HNSCC patients from initial disease staging
and therapy planning to patient surveillance.
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Head and neck squamous cell carcinoma (HNSCC) is
one of the most common cancers in the world, with an
incidence of approximately 600,000 new cases per year
[1]. Despite different strategies employed in the treat-
ment of HNSCC patients, including surgery, radiother-
apy, and chemotherapy, late diagnosis and the frequent
development of loco-regional recurrences frequently
contribute to treatment failure and low rates of overall
survival observed [2].
The involvement of neck lymph nodes in HNSCC pa-
tients significantly reduces the odds for disease control.
The 5-year survival rate for patients without lymph node
metastases is 63% to 86%, while patients with neck me-
tastases have rates of 20% to 36% [3-6]. Besides being an
important prognostic indicator, the presence of meta-
static disease in lymph nodes also influences the choice
of the adjuvant therapy used to reduce disease recur-
rence [7-9]. Therefore, assessment of the neck has be-
come an integral part of the treatment planning for
HNSCC patients.
There is a well-accepted strategy for the treatment of
patients with clinically positive lymph nodes, which
includes therapeutic neck dissection followed by postop-
erative radiotherapy with or without concurrent chemo-
therapy. However, the treatment choice for patients
without clinical evidence of neck metastases remains
controversial [10,11]. Initial tumors are highly curable by
surgery or radiotherapy alone. For this reason, a ‘wait-
and-see’ approach, in which the neck is not treated and
the patient is followed and monitored with special atten-
tion to the evolution of disease in cervical lymph nodes
is acceptable. Nevertheless, studies have shown that 30%
to 60% of cases with initial tumors will present cervical
metastases [12-14]. On the other hand, the use of elect-
ive neck dissection for all patients with early tumors and
clinical and radiological N0 necks at high risk of harbor-
ing subclinical disease in the lymph nodes (mainly
tongue and floor of the mouth sites, T2 tumors with
high depth of invasion) is also defended [15]. Although
some studies showed a better loco-regional control and
longer regional disease-free survival for patients submit-
ted to elective neck dissection [16,17], only 20% to 50%
will actually harbor metastatic disease in their lymph
nodes. In other words, 50% to 80% of these patients
were subjected to the morbidity of unnecessary surgical
treatment [12-14,16,18].
A limitation for the correct evaluation of neck metas-
tases in HNSCC patients is the lack of sufficient sensitiv-
ity of the postoperative assessment of lymph nodes by
formalin-fixed tissue sections stained with hematoxylin
and eosin (H&E), especially regarding small metastatic
deposits. Studies show that 10% to 40% of HNSCC pa-
tients with histopathologically negative neck lymphnodes eventually develop regional metastases, suggesting
that metastatic cells present in the lymph nodes could
not be detected at diagnosis [12,19,20]. In line with this,
5% to 20% of lymph nodes previously classified as
metastasis-free by routine histopathological evaluation
present positivity for cytokeratins in immunohistochemi-
cal (IHC) analysis [21-25]. To overcome this problem,
molecular detection of metastases seems to be one of
the most promising methods for definitive lymph node
evaluation. Through this approach, metastatic deposits
in lymph nodes can be detected in a more sensitive, ac-
curate, and less time-consuming manner. Toward this
end, the identification of molecular markers capable of
detecting the presence of metastatic cells in a back-
ground of lymphatic cells is mandatory.
MicroRNAs are small non-coding RNA molecules of
approximately 22 nucleotides, described as regulators of
gene expression in a variety of multicellular organisms
[26,27]. These small molecules interact mainly with the
3′-untranslated regions of specific messenger RNAs
(mRNA), inducing their degradation or inhibiting their
translation [26,27]. Specific microRNA expression has
been observed in different cancer types and at distinct
differentiation stages [28-31]. These molecules also play
an important role in the development of head and neck
cancers. HNSCC-specific microRNA expression profiles
and key microRNAs known to orchestrate gene and
protein expression levels in these tumors have been
established [32]. Recent studies have highlighted differ-
ent applications of these molecules as biomarkers in
HNSCC, such as in the detection of HNSCC cells in sal-
iva samples, in the identification of human papilloma
virus-positive oropharyngeal tumors, or as prognostic
markers associated with disease progression [32-36].
Furthermore, Fletcher et al. [37] found that the expres-
sion of miR-205 was specific to metastatic lymph nodes
of HNSCC patients.
In this article, we report the identification of micro-
RNAs capable of detecting metastatic cells in formalin-
fixed paraffin-embedded (FFPE) lymph nodes and in
fine-needle aspiration (FNA) biopsies of HNSCC pa-
tients with high sensitivity, specificity, and accuracy.
Methods
Population cohorts
The current study included retrospective and prospect-
ive cohorts. The retrospective cohort involved FFPE
neck lymph node samples from 48 patients surgically
treated between 2000 and 2012 at the Department of
Head and Neck Surgery, Barretos Cancer Hospital,
Barretos, SP, Brazil. The inclusion criteria of this cohort
were patients with primary SCC of the oral tongue, floor
of mouth, lower gum, and retromolar area; classified as
T1-T2-T3 stages and without clinical and radiological
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nosis; submitted to surgery as the first therapeutic
modality for treatment of the primary tumor; plus
elective supraomohyoid neck dissection or sentinel
lymph node evaluation. The use of these samples was
approved by the Barretos Cancer Hospital Institutional
Review Board.
The prospective cohort was comprised by FNA biop-
sies of resected lymph nodes from 79 patients who
received treatment between 2013 and 2014 at the
Department of Head and Neck Surgery of the Barretos
Cancer Hospital, Barretos, SP, Brazil. This cohort in-
cluded HNSCC patients, regardless of tumor site or
stage, who underwent neck dissection during the sur-
gery of the primary tumor, as a salvage treatment
after organ preservation protocol, or for the treat-
ment of patients who developed neck metastases dur-
ing follow-up. Informed consent was obtained from
each individual prior to tissue collection and the study
protocol was approved by Barretos Cancer Hospital
Institutional Review Board.
Study design
This study can be divided into three distinct phases.
Firstly, a ‘discovery set’ comprising metastatic and non-
metastatic FFPE lymph nodes from patients with tumors
in the oral cavity was evaluated in order to select prom-
ising markers to be tested in a larger sample cohort.
This analysis allowed the selection of good candidates to
be evaluated in a ‘validation set’ containing an additional
group of metastatic and non-metastatic FFPE lymph
nodes from patients presenting oral cavity tumors. This
analysis identified microRNAs with high sensitivity and
specificity in detecting the presence of metastatic cells inFigure 1 Schematic representation of lymph nodes sectioning protocol fo
analyses. (A) Non-metastatic lymph nodes: all sections at different levels we
(B) Metastatic lymph nodes: only sections of the positive level at IHC analy
(arrow). The leftover material (regions marked with “*”) removed from each
leftover material.lymph nodes. Later, the accuracy of these markers was
evaluated in an independent prospective cohort of FNA
samples collected from negative and positive lymph
nodes from HNSCC patients harboring tumors in the
oral cavity, pharynx, and larynx.
FFPE samples processing and RNA purification
H&E sections corresponding to paraffin blocks contain-
ing the samples of interest were reviewed by a patholo-
gist to confirm the diagnosis and for characterization of
the cellular components present in the samples.
To confirm the absence of metastatic deposits in his-
tologically free-of-metastases cases, the blocks contain-
ing all lymph nodes resected from each patient were
step-sectioned at 50 μm intervals and six sections with a
thickness of 5 μm each were obtained from each level
(Figure 1). The first section was examined by IHC ana-
lysis for the expression of cytokeratins, while the
remaining five sections were used in molecular analyses.
Samples were finally classified as negative when the
specimen contained no tumor cells (no positivity for
cytokeratins) and positive when isolated tumor cells
(<0.2 mm), micrometastasis (0.2–2.0 mm), or macrome-
tastasis (>2.0 mm) were detected.
We also challenged the selected markers to detect the
presence of metastatic cells in the leftover material
removed from each level (intervals of 50 μm) of the
step-sectioned FFPE lymph nodes examined in the IHC
analyses (Figure 1).
For RNA extraction from FFPE positive lymph node
cases, macrodissection was applied to five paraffin-
embedded sections to collect the metastatic deposit
prior to RNA extraction. For the non-metastatic FFPE
cases, total RNA was extracted from sections obtainedr immunohistochemistry (solid line) and molecular (dotted line)
re used for RNA extraction and subsequent molecular analysis (arrows).
sis were used for RNA extraction and subsequent molecular analysis
interval of 50 μm was collected and used in the analysis of the
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isolated using the Recoverall Total Nucleic Acid Isolation
kit (Ambion, Austin, TX, USA), which contains a DNAse
treatment step. Total RNA was quantified in the Qubit
fluorometer (Invitrogen, Carlsbad, CA, USA) and stored
at −80°C until use.
Due to the scarcity of RNA quantity yielded from
FFPE samples, no step for evaluation of the RNA purity
or integrity was performed. The amplification of the
internal controls (U6 and U47) by qPCR was used as
indicative of the high quality of the RNA samples. It is
important to mention that all samples included in the
study showed amplification of both internal controls at
early cycles.
Fine-needle aspiration biopsies processing and RNA
purification
The material collected through FNA of the resected
lymph nodes was used to perform a smear, and the
slides were stained to enable the cytological diagnostic
of the lymph nodes as ‘positive’ or ‘negative’ for the pres-
ence of metastatic cells. The remaining material on the
needle was washed in 200 μL of sterile saline solution
and ethylenediaminetetraacetic acid, snap frozen, and
stored at −80°C until RNA extraction.
The extraction of total RNA from FNA samples was
performed using the Trizol reagent (Invitrogen, Carlsbad,
CA, USA) as previously described [38]. Total RNA was
quantified in the Qubit fluorometer (Invitrogen) and stored
at −80°C until use.
Global microRNA profiling by TaqMan human MicroRNA
arrays
In the ‘discovery set’, a global microRNA expression pro-
filing was performed in lymph nodes from six FFPE oral
tongue SCC samples (four with macrometastases and
two with non-metastatic nodes) using TaqMan Human
MicroRNA Arrays (Applied Biosystems, Foster City,
CA, USA).
Total RNA (40 ng) from each lymph node sample
were reverse transcribed into cDNA using the TaqMan
microRNA Kit and Megaplex RT Primers (both from
Applied Biosystems). After synthesis, the cDNA was
pre-amplified using the TaqMan PreAmp Master Mix
Kit and Megaplex PreAmp Primers (Applied Biosys-
tems). The amplified-cDNA was then transferred to the
TaqMan Human MicroRNA Array plates and the ampli-
fication was carried out in an Applied Biosystems
7900HT Real-Time PCR system.
The data obtained was analyzed using the software
DataAssist v3.0 (Applied Biosystems). The fold-change
difference between metastatic and non-metastatic lymph
node samples was calculated using the 2-ΔΔCt method
[39]. The small nuclear RNA U6 was used as anendogenous control and the non-metastatic group was
assigned as a reference since this was the most stable
control in the assay.
Validation of differentially expressed microRNAs by
real-time PCR
The ‘validation set’ included 48 FFPE lymph node sam-
ples and 113 FNA lymph node biopsies from HNSCC
patients. Each assay was conducted using the Taqman
MicroRNA Reverse Transcription kit (Applied Biosystems)
according to the manufacturer’s protocols. Briefly, 10 ng
of total RNA was reverse-transcribed to cDNA using a
MultiScribe Reverse Transcriptase and a stem-loop primer
(Applied Biosystems) specific for each selected microRNA
according to manufacturer’s instructions. Quantitative
real-time PCR (qRT-PCR) was performed using a TaqMan
PCR kit on a 7500 Fast Real-Time PCR System (Applied
Biosystems). All reactions were performed in triplicate. To
evaluate the differential expression of each microRNA
between metastatic and non-metastatic lymph nodes, the
2-ΔΔCt method was employed [39]. The ratio between the
average Ct values of each microRNA and the internal con-
trols (U6 and U47) in 10 non-metastatic lymph node sam-
ples was used as reference in the 2-ΔΔCt formula.
Statistical analysis
In the discovery set, to search for differentially expressed
microRNAs in metastatic and non-metastatic lymph
nodes, a global microRNA expression profiling was con-
ducted. In this analysis, ΔCt values from each microRNA
were evaluated by the non-parametric Rank Products
test using the RankProd R package [40]. The Rank
Products test is a robust tool to perform ranking lists
with high performance on biological validation. This
method did not give any assumption on the data dis-
tribution, but provided frequency-based ranking scores.
In the validation sets (FFPE and FNA), differentially
expressed microRNAs were identified using the Mann–
Whitney U test.
A receiver operating characteristic (ROC) curve was
constructed with the expression levels of each micro-
RNA of interest in the metastatic and non-metastatic
samples. The ROC curve is a plot of sensitivity (Se)
versus 1-specificity (1-Sp) at all possible expression
levels (c). In the FFPE validation set, a cutoff value was
determined for each individual marker to maximize the
classification accuracy according to the Youden index.
The Youden Index (J) is a way to summarize ROC curve
statistics in the interpretation and evaluation of a bio-
marker. It defines the maximum potential effectiveness
of a biomarker and can be formally defined as J = max c
{Se(c) + Sp (c) − 1} (value in which the difference be-
tween sensitivity and 1-specificity is maximum) [41]. For
the FNA validation set, a 10-fold cutoff level was
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ducibility of the tests.
The area under the ROC curve (AUC) was able to
identify optimal sensitivity and specificity levels to dis-
tinguish metastatic samples from non-metastatic ones.
Sensitivity, specificity, accuracy, and positive and nega-
tive predictive values (PPV and NPV) of each individual
microRNA in distinguishing metastatic from non-
metastatic samples were also calculated along with
95% confidence intervals (95% CI). For FNA samples,
the agreement between molecular findings with cyto-
logical and histological diagnostic was assessed using
the Kappa test.
All two-tailed P values were derived from statistical
tests, using a computer-assisted program (IBM SPSS
Statistics, Version 19), and considered statistically signifi-
cant at P <0.05.
Results
Patient characteristics
Clinical and histopathological data of the patients en-
rolled in this study are presented in Additional file 1:
Tables S1 and S2.
For the FFPE series, of the 48 patients profiled in this
cohort, 47.9% were smokers, 79.2% were males, and the
age ranged from 43 to 84 years (median 60 years). Pri-
mary tumor sites were oral tongue (58.3%), floor of
mouth (31.3%), alveolar ridge (8.3%), and lower gum
(2.1%) and most were cT2 (62.5%). All patients in this
cohort underwent surgery as the primary modality of
treatment, and 23 (47.9%) received adjuvant radiation or
chemo-radiation therapy.
For the FNA cohort, of the 79 patients included in this
cohort, 76% were smokers and 88.6% were males, with
age ranging from 29 to 78 years (median 57 years). The
primary tumor sites were oral cavity (59.5%), oropharynx
(19.0%), larynx (15.2%), and hypopharynx (6.3%) and
78.5% had advanced disease (III–IV). All patients in this
cohort underwent neck dissection either during the sur-
gery of the primary tumor (69.6%), as a salvage treat-
ment after organ preservation protocol (24.1%), or for
the treatment of patients who developed neck metasta-
ses during follow-up (6.3%).
Identification of metastatic cell deposits in FFPE and FNA
lymph node samples
A total of 356 lymph nodes resected from the 48 pa-
tients included in the FFPE cohort were examined
through H&E to provide the histologic diagnostic of the
lymph nodes for the presence of metastatic cells. All
histologically-free of metastases lymph nodes were fur-
ther step-sectioned and submitted to IHC for cytokera-
tins to confirm the absence of metastatic cells and to
identify possible small metastatic deposits. Therefore, ofthe 48 patients included in the FFPE cohort, 25 harbored
metastatic lymph nodes (18 with macrometastases, 5
with micrometastases, and 2 with isolated tumor cells)
and 23 samples had metastases-free lymph nodes
(Figure 2).
Overall, 113 FNA biopsies were collected from lymph
nodes resected from 79 patients submitted to neck dis-
section. During the collection, whenever possible, FNA
biopsies were conducted in macroscopically positive and
negative lymph nodes from the same patient. These
samples were further classified as ‘positive’ or ‘negative’
according to the cytological examination of the lymph
node biopsies. Moreover, the resected lymph nodes were
processed according to the routine of the Department of
Pathology and H&E sections were assessed to provide
the histologic diagnostic of the lymph nodes as ‘positive’
or ‘negative’ for the presence of metastatic cells. For
three of the 113 FNA samples, there was a disagreement
between histological and cytological diagnostics. While
the cytological smears were classified as negative in all
three samples, the histological assessment found micro-
metastatic deposits in two cases and isolated tumor cells
in the third one. Thus, according to the cytological
evaluation, 42 (37.2%) of the FNA samples collected
were classified as positive and 71 (62.8%) as negative; in
the histological evaluation, 45 (39.8%) were classified as
positive and 68 (60.2%) were classified as negative for
the presence of metastatic epithelial cells.
Global microRNA profiling in lymph node samples
Comprehensive microRNA profiles were generated for
metastatic (n = 4) and non-metastatic (n = 2) lymph
nodes from HNSCC patients using a quantitative RT-
PCR array platform. From a total of 667 microRNAs,
439 were detected in at least two samples, regardless of
the group, thereby serving as the pool of data for further
analyses. From those, 61 presented a P <0.05 in the Rank
Products test with 47 showing at least two-fold upregu-
lation in all four metastatic samples. A non-supervised
hierarchical clustering analysis using the ΔCt values of
these 47 microRNAs displayed two distinct clusters
formed by metastatic and non-metastatic lymph nodes
(Figure 3). Finally, seven microRNAs (miR-200a, miR-
200c, miR-203, miR-205, miR-382, miR-628-5p, miR-758),
presenting more than 100-fold increment in the expression
level in metastatic lymph nodes, were selected for further
analyses (Table 1).
Evaluation of the differentially expressed microRNAs in
FFPE samples
Due to the scarcity of RNA quantity recovery from the
FFPE samples, the evaluation of the expression profile
of the selected microRNAs in the FFPE ‘validation set’
was performed in two stages. In the first series, the
Figure 2 Immunohistochemistry staining for cytokeratins (M3515, clone AE1/AE3, Dako) in histologically negative lymph nodes of HNSCC
patients. (A) Lymph node without evidence of metastases. (B) Lymph node with macrometastases. (C) Lymph node with micrometastases.
(D) Lymph node with isolated tumor cells. A, B, and C: 40× magnification; D: 400× magnification.
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‘discovery set’ (miR-200a, miR-200c, miR-203, miR-205,
miR-382, miR-628-5p, and miR-758) was examined in 19
positive lymph nodes (14 macrometastases and 5 micro-
metastases) and in 13 negative lymph nodes (of the 23
patients with negative lymph nodes included in this
study, 10 were used as a control reference, as indicated
in Methods section).
This analysis showed that miR-628-5p, miR-758, and
miR-382, were only able to detect 26.3%, 31.6%, and
52.6% of the metastatic samples, respectively, reflecting
a low sensitivity (Additional file 1: Table S3, Additional
file 2: Figure S1) and were excluded from the study. On
the other hand, miR-200a, miR-200c, miR-203, and miR-
205 presented maximum specificity (100%) and high
sensitivity (84.2%, 94.7%, 100%, and 100%, respectively)
(Additional file 1: Table S3). Therefore, in the second
series, these four microRNAs were tested in the ex-
panded cohort of samples (25 metastatic and 23 non-
metastatic lymph nodes).
The Youden index obtained from ROC curves was
used to determine the cutoff values for upregulation of
miR-200a, miR-200c, miR-203, and miR-205, which var-
ied from 1.54 to 5.96 (Table 2, Figure 4). The expression
profile of these four microRNAs in the metastatic and
non-metastatic FFPE lymph node samples showed they
were highly associated with the presence of metastaticcells in the neck lymph nodes of HNSCC cases (miR-
200a, 76%; miR-200c, 88%; miR-203, 100%; miR-205,
100%; Figure 5, Table 2). However, miR-200a and miR-
200c barely detected the presence of micrometastases
(40% and 80%, respectively), and failed in detecting cases
with isolated tumor cells. On the other hand, miR-203
and miR-205 displayed high sensitivity levels (100%) and
were also able to correctly classify lymph nodes contain-
ing macrometastases, as well as micrometastases or
isolated tumor cells (Table 2).
Diagnostic accuracy of microRNAs in FFPE lymph node
samples
The diagnostic accuracy of miR-200a, miR-200c, miR-
203, and miR-205 in differentiating lymph nodes with
and without metastases was assessed. The accuracy of
miR-200a was 84.2% (95% CI, 68.1–93.4%), the positive
predictive value was 100%, and the negative predictive
value was 68.4% (95% CI, 43.5–87.3%). The accuracy of
miR-200c was 92.1%, the positive and negative predictive
values were of 100% and 81.2% (95% CI, 77.5–97.9%), re-
spectively. For miR-203 and miR-205, both positive and
negative predictive values, as well as the accuracy levels,
were of 100% and AUC of 1.0 (Table 3).
Since miR-203 and miR-205 showed a high accuracy
in identifying metastatic lymph nodes, the ability of these
markers in detecting metastatic cells in a background of
Figure 3 Heatmap representations of the 47 differentially expressed
microRNAs with fold-change ≥2 and P value <0.05 (Rank Products)
in the comparison between four metastatic lymph nodes (M: 7A, 1A,
8A, and 9A) and two non-metastatic lymph nodes (NM: 4C and 5C)
resected from patients with T2N0 tongue squamous cell carcinomas.
Non-supervised hierarchical clustering plotted based on the average
ΔCt values. Up-regulated and down-regulated microRNAs are shown
as red and blue, respectively. The columns represent samples and
the microRNAs differentially expressed are shown in the lines.
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microRNAs was examined in the leftover material removed
from the step-sectioned lymph nodes during IHC analyses.
According to immunostaining, these samples harbored
macrometastases (n = 5), micrometastases (n = 4), and
isolated tumor cells (n = 2). As shown in Additional
file 2: Figure S2, expression levels above the cutoff
value could be detected in all lymph nodes carrying
metastatic cells, while the expression in the non-
metastatic samples was always bellow the cutoff. These
results suggested that the evaluation of miR-203 and
miR-205 expression still presents high sensitivity and
specificity even when the metastatic deposit is ‘diluted’ in
a background of lymphoid tissue.Validation and diagnostic accuracy of miR-203 and
miR-205 expression in FNA samples
Given the high accuracy of miR-203 and miR-205 in de-
tecting metastases in FFPE lymph node samples, we de-
cided to evaluate these markers in FNA biopsies of
lymph nodes from HNSCC patients.
The accuracy of both markers in detecting metastatic
deposits in the FNA biopsies was compared with the re-
sults obtained from cytological assessment, which had
detected 42 positive FNA samples and 71 negative ones
for the presence of epithelial cells. This analysis showed
a complete concordance between the cytological andTable 1 Seven microRNAs highly upregulated in
metastatic lymph node samples collected from HNSCC
patients according to the global microRNA profiling
using the TaqMan human microRNA array cards
microRNAs Mean fold-change P value*
miR-200a 594 0.008
miR-200c 628 0.006
miR-203 2169 0.001
miR-205 1648 0.0001
miR-382 82984 <0.00001
miR-628-5p 1564 0.01
miR-758 182 0.01
*Rank products.
Table 2 Sensitivity and specificity values of microRNAs evaluated in discriminating metastatic and non-metastatic
lymph nodes in FFPE and FNA biopsies from lymph node samples
microRNA Sensitivity Specificity
Cutoffa Metastaticb Macrometastases Micrometastases Isolated tumor cells Non-metastatic
% (95% CI) (n) % (95% CI) (n) % (95% CI) (n) % (95% CI) (n) % (95% CI) (n)
FFPE samples
miR-200a 5.96 76.0 (54.5–89.8) (19/25) 94.4 (70.6–99.7) (17/18) 40.0 (7.3–82.9) (2/5) 0 (0–80.2) (0/2) 100 (71.7–100) (13/13)
miR-200c 2.33 88.0 (67.7–96.8) (22/25) 100 (78.1–100) (17/18) 80.0 (29.9–98.9) (4/5) 0 (0–80.2) (0/2) 100 (71.7–100)) (13/13)
miR-203 1.96 100 (83.4–100) (25/25) 100 (78.1–100) (17/18) 100 (46.3–100) (5/5) 100 (19.8–100) (2/2) 100 (71.7–100) (13/13)
miR-205 1.54 100 (83.4–100) (25/25) 100 (78.1–100) (17/18) 100 (46.3–100) (5/5) 100 (19.8–100) (2/2) 100 (71.7–100) (13/13)
FNA samples classified by cytology
miR-203 10 100 (91.5–100) (42/42) 100 (91.5–100) (42/42) N/A N/A 100 (94.9–100) (71/71)
miR-205 10 100 (91.5–100) (42/42) 100 (91.5–100) (42/42) N/A N/A 100 (94.9–100) (71/71)
FNA samples classified by histology
miR-203 10 92.9 (80.5–98.4) (68/71) 100 (89.3–100) (68/68) 0 (0) (0/2) 0 (0) (0/1) 100 (94.9–100) (71/71)
miR-205 10 92.9 (80.5–98.4) (68/71) 100 (89.3–100) (68/68) 0 (0) (0/2) 0 (0) (0/1) 100 (94.9–100) (71/71)
FFPE, Formalin-fixed paraffin embedded; FNA, Fine-needle aspiration; PPV, Positive predictive value; NPV, Negative predictive value; AUC, Area under the ROC curve;
CI, Confidence interval; N/A, Not applicable. aThe cutoff values for FFPE samples were determined according to the Youden index (value in which the difference
between sensitivity and 1-specificity is maximum) obtained from the ROC curves. bThe ‘metastatic’ group comprises all cases with positive lymph nodes
(macrometastases, micrometastases, or isolated tumor cells).
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negative nodes with a Kappa value of 1.000. All 42
positive and 71 negative FNA on the cytological assess-
ment were correctly identified by both markers with a
sensitivity rate of 100% (42/42, CI 95%, 91.5–100) and
a specificity level of 100% (71/71, CI 95%, 94.9–100)
(Table 2; Figure 6A). A high accuracy of both miR-203
and miR-205 was observed with an AUC of 1.00
(Table 3; Figure 7A), negative and positive predictive
values of 100% (95% CI, 94.9–100 and 95% CI, 91.5–
100, respectively), and accuracy levels of 100% (95% CI,
96.05–100) (Table 3).
Next, the results obtained from the histological evalu-
ation (after lymph node excision), which is considered
the definitive classification of lymph nodes according to
the metastatic status, were compared with the molecular
analyses of the FNA samples using both miR-203 and
miR-205. The histological analyses found 45 positive
FNA and 68 negative biopsies. There was an agreement
of 100% between both approaches in detecting negative
lymph nodes and of 93.3% in classifying positive ones
(Kappa value = 0.944). Only three metastatic samples
(6.7%) were not detected in FNA samples using the
molecular markers, the same ones harboring micro-
metastases and isolated tumor cells identified only in
the H&E sections (after lymph node excision) and
not detected by cytological assessment. This result
suggests that small clusters of cells cannot be repre-
sented during the aspiration, which would preclude
its detection through cytological and molecular
methods. All in all, the sensitivity rate for both markerswas 92.9% (39/42, CI 95%, 80.5–98.4), with a specificity
level of 100% (71/71, CI 95%, 94.9–100) (Table 2;
Figure 6B). A high accuracy of both miR-203 and miR-
205 in distinguishing positive and negative FNA with
AUC of 0.963 and 0.966, respectively, and accuracy levels
of 97.3% (95% CI, 92.1–99.4) were also observed (Table 3;
Figure 7B). Moreover, negative predictive values were of
95.9% (95% CI, 88.6–99.1%) and positive predictive
values of 100% (95% CI, 90.9–100%) for both microRNAs
(Table 3).
Discussion
HNSCC is a heterogeneous group of tumors that arises
from multiple factors that alter different pathways con-
tributing to its development and progression. The pres-
ence of lymph node metastases is determinant for
prognosis and significantly reduces the effectiveness of
disease control [7,9,42]. Thus, the accurate detection of
lymph node metastases in HNSCC patients is of para-
mount importance for its correct staging and more
effective treatment planning.
Although the H&E-based pathologic examination of
these tumors is very sensitive for macrometastases de-
tection, smaller metastatic deposits are difficult to iden-
tify and the correct diagnosis relies on the slide quality,
operator’s proficiency, sensitivity of the method, and,
often, the need for IHC. Although IHC is a more sensi-
tive alternative, it is a laborious and time-consuming
analysis that demands the investigation of serial sections
from different levels of each lymph node excised from
the patient. Therefore, even though a more detailed
Figure 4 ROC (Receiver Operating Characteristic) curves obtained for microRNAs miR-200a, miR-200c, miR-203, and miR-205 in the FFPE
validation set.
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more accurate information about metastases, this in-
volves a long time for preparation of the specimens and
a heavy workload for pathologists to examine them.
Taken together, all these limitations highlight the need
for new molecular markers to complement the patho-
logical methods in the task of detecting metastatic cells
in lymph nodes of HNSCC patients.
In an initial ‘discovery set’ analysis, the expression pat-
tern of 667 microRNAs was compared between meta-
static and non-metastatic lymph nodes and, after
filtering steps, seven microRNAs were chosen to be ex-
amined in a FFPE ‘validation set’. From those, miR-200a
and miR-200c showed high levels of specificity and sen-
sitivity, while miR-203 and miR-205 were able to detect
even small metastatic deposits such as micrometastases
or isolated tumor cells. Such high accuracy levels attestthe feasibility of using these markers in the clinical prac-
tice as an additional tool to help pathologists in the
correct assessment of lymph node status of HNSCC
patients harboring sub-clinical neck metastases.
The sentinel node biopsy is a technique of cervical
lymph node staging in patients with primary tumors,
allowing a more detailed histological, immunohisto-
chemical, and molecular search for occult neck metasta-
ses. Usually, the histopathological evaluation of sentinel
lymph nodes is based on immunohistochemistry analysis
of serial sections, requiring a long time for the final diag-
nosis [43]. Consequently, the delay in the correct diag-
nosis of the malignancy may lead to the need of
additional surgeries, increasing the risk of post-operative
complications and functional problems, as well as post-
poning the beginning of the adjuvant treatment [44,45].
In the present study, miR-203 and miR-205 were able to
Figure 5 Expression profile of miR-200a, miR-200c, miR-203, and miR-205 in lymph node samples containing macrometastases (Ma; n = 18),
micrometastases/isolated tumor cells (Mi and isolated tumor cells; n = 7), or in non-metastatic lymph node specimens (NM; n = 13). The Y-axis shows
the log10 fold-change of the relative expression (2
-ΔΔCt). The P value (Mann–Whitney) from each comparison is provided. The dotted line indicates the
cutoff adopted according to the Youden index (value in which the difference between sensitivity and 1-specificity is maximum) obtained from the
ROC curves analysis. The horizontal line indicated the median of fold-change values for each group.
Table 3 Accuracy characteristics of microRNAs in discriminating metastatic and non-metastatic lymph nodes in FFPE
and FNA biopsies from lymph node samples
microRNA PPV NPV Accuracy AUC (95% CI)
% (95% CI) % (95% CI) % (95% CI)
FFPE samples
miR-200a 100 (82.2–100.0) 68.4 (43.5–87.3) 84.2 (68.1–93.4) 0.92 (0.83–0.99)
miR-200c 100 (84.4–100.0) 81.2 (54.34–95.73) 92.1 (77.5–97.9) 0.94 (0.85–1.0)
miR-203 100 (86.2–100) 100 (75.1–100) 100 (88.6–100) 1.0 (0–1.0)
miR-205 100 (86.2–100) 100 (75.1–100) 100 (88.6–100) 1.0 (0–1.0)
FNA samples classified by cytology
miR-203 100 (91.5–100) 100 (94.9–100) 100 (96.05–100) 1.0 (0–1.0)
miR-205 100 (91.5–100) 100 (94.9–100) 100 (96.05–100) 1.0 (0–1.0)
FNA samples classified by histology
miR-203 100 (90.9–100) 95.9 (88.6–99.1) 97.3 (92.1–99.4) 0.963 (0.921–1.0)
miR-205 100 (93.2–100) 94.6 (85.1–98.8) 96.7 (93.1–100) 0.966 (0.921–1.0)
FFPE, Formalin-fixed paraffin embedded; FNA, Fine-needle aspiration; PPV, Positive predictive value; NPV, Negative predictive value; AUC, Area under the ROC
curve; CI, Confidence interval.
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Figure 6 Expression profile of miR-203 and miR-205 in FNA biopsies from lymph nodes classified as positive (FNA+) or negative (FNA–) according
to (A) cytological diagnostic (FNA+: n = 42; FNA–; n = 71) and (B) histological diagnostic (FNA+: n = 45; FNA–; n = 68). The Y-axis shows the log10
fold-change of the relative expression (2-ΔΔCt). The P value (Mann–Whitney) from each comparison is provided. The dotted line indicates the
10-fold cutoff adopted.
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lymph node samples containing large amounts of lym-
phocytes and lymphoid stroma. This highlights the high
sensitivity of these markers in detecting epithelial cells
in a lymphoid tissue background, allowing the correct
detection of metastases in entire lymph nodes and avoid-
ing false negative results related to partial lymph node
assessment. Moreover, a methodology for automated
qRT-PCR-based gene expression analysis in an average
time of 35 minutes has been described recently [46].
Taken collectively, these results suggest the feasibility of
performing microRNA marker analysis in sentinel lymph
nodes in a time consistent with an intraoperative evalu-
ation, which can be a relevant tool to assist the surgeon
in deciding the best approach to be adopted in the neck
treatment.
The biopsy based on cytological analysis of FNA sam-
ples is a minimally invasive method of high accuracy for
the diagnosis of lesions in various organs. Its diagnostic
accuracy depends on several factors, such as site, type of
injury, the experience of the professional collecting the
sample, the quality of the preparation, and the diagnostic
skills of the cytopathologist [47,48]. This study showedthat the comparison between cytology assessment, hist-
ology examination, and molecular analysis presented
high levels of agreement in detecting metastatic cells in
lymph nodes. Both cytology and molecular assays could
not detect the presence of tumor cells in three FNA
samples containing micrometastases or isolated tumor
cells. We believe that the misclassification of these three
false-negative samples was due to sampling errors repre-
sented by the absence of metastatic cells in the FNA
specimen. Since metastatic cells were not aspirated, they
were not present in the cytological smear and conse-
quently were also absent in the sample obtained from
washing the aspiration needle. Apart from those, all
FFPE samples harboring micrometastases (according to
pathological evaluation) could be correctly identified
through the use of these molecular markers. Moreover,
it is important to note that 30.4% of the FNA samples
were collected from patients that have received previous
radiotherapy treatment on the neck. Thus, the effects of
radiation on lymph node tissues (hence, presence of
necrosis and keratin granuloma) did not hinder the cor-
rect identification of metastatic cells on these samples.
Even though the molecular approach did not show an
Figure 7 Receiver Operating Characteristic curves obtained for microRNAs miR-203 and miR-205 in in FNA biopsies from lymph nodes classified
as positive (FNA+) or negative (FNA–) according to (A) cytological diagnostic and (B) histological diagnostic.
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logical assessment, we believe that its use is warranted
given that, unlike molecular assessment, the accuracy of
cytological assessments is highly dependent on the qual-
ity of the preparation and the diagnostic skills of the
cytopathologist. The results obtained with the analysis of
FNA samples indicate a high specificity and sensitivity of
miR-203 and miR-205 to detect the presence of meta-
static cells in the FNA biopsy samples, suggesting their
role in a future pre-treatment or follow-up test of suspi-
cious lymph nodes in HNSCC patients.
Conclusions
To the best of our knowledge, this is the first study to
demonstrate the usefulness of miR-203 and miR-205expression as a sensitive, specific, and accurate mo-
lecular approach for the diagnosis of cervical lymph
node metastases. This molecular approach can be
used i) at diagnosis, by analyzing samples collected
by FNA biopsies, ii) in post-surgery analyses, as de-
scribed in this work, as a tool to assist the histo-
pathological examination, allowing the investigation
of entire lymph nodes and reducing sampling bias,
iii) during surgery as an alternative tool for examining
sentinel lymph nodes, and iv) during patient follow-up
for the testing of suspicious lymph nodes, again, evaluat-
ing FNA biopsies.
Our results suggest that the evaluation of miR-203
and miR-205 expression could be an important tool for
the management of HNSCC patients, assisting in the
de Carvalho et al. BMC Medicine  (2015) 13:108 Page 13 of 14stratification of patients that may harbor neck metasta-
ses, aiding in therapy planning and patient surveillance,
ultimately contributing to an improvement in quality of
life and survival rates.
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